Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma
DOI:
https://doi.org/10.17140/POJ-1-107Keywords:
Pancreatic cancer; Pancreatic ductal adenocarcinoma; Desmoplastic/stromal reaction; Tumor-stroma interactions.Abstract
Despite significant effort and research funds, Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the deadliest diseases. This cancer is characterized by a distinct des-moplastic reaction that constitutes 80% of the tumor volume. Accumulating evidences suggests that the stromal compartment in which the cancer cells are embedded contributes to many clini-cal characteristics of pancreatic cancer. The stromal compartment is comprised of abundant extracellular matrix (ECM), fibroblasts, stellate cells, immune cells, nerve cells, growth factors and cytokines. To date, desmoplastic reaction components have been shown not only to con-tribute to the growth and metastasis of pancreatic cancer but also to chemotherapy resistance. Therefore, further assessment of stroma-targeted therapies and their translation into clinical situation may open a new era in pancreatic cancer management.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29. doi: 10.3322/caac.21254
Ying H, Dey P, Yao W, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016; 30(4): 355-385. doi: 10.1101/gad.275776.115
Seymour AB, Hruban RH, Redston M, et al. Allelotype of pancreatic adenocarcinoma. Cancer Res. 1994; 54(10): 2761- 2764. Web site. http://cancerres.aacrjournals.org/content/54/10 /2761.short. Accessed February 29, 2016.
Ruckert F, Grutzmann R, Pilarsky C. Feedback within the inter-cellular communication and tumorigenesis in carcinomas. PLoS One. 2012; 7(5): e36719. doi: 10.1371/journal.pone.0036719 Effect Model References Survival rate↑ In mouse models 59 Tumor volume↓ Orthotopic model of metastasis↓ pancreatic cancer Patient-tumor-derived Stroma↓ subcutaneous xenograft 67,68 model ery↑ Tumor bearing KPC mice 24 Median survival↑ owth↓ Subcutaneous mouse model Advanced pancreatic Anti-tumor activity↑ 70 cancer patients
Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem. 2007. 101(4): 887- 907. doi: 10.1002/jcb.21209
Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas. 2004; 29(3): 179-187. Web site. http://journals.lww.com/ pancreasjournal/Abstract/2004/10000/Desmoplastic_Reaction_ in_Pancreatic_Cancer_Role.2.aspx. Accessed February 29, 2016.
Lunardi S, Muschel RJ, Brunner TB. The stromal compartments in pancreatic cancer: are there any therapeutic targets? Cancer Lett. 2014. 343(2): 147-155. doi: 10.1016/j. canlet.2013.09.039
Grzesiak JJ, Bouvet M. The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br J Cancer. 2006; 94(9): 1311-1319. doi: 10.1038/ sj.bjc.6603088
Dangi-Garimella S, Krantz SB, Barron MR, et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011; 71(3): 1019-1028. doi:
1158/0008-5472.CAN-10-1855 10. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S, et al. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004; 28(1): 38-44. Web site. http://journals.lww. com/pancreasjournal/Abstract/2004/01000/Tumor_Stroma_ Interaction_of_Human_Pancreatic.6.aspx. Accessed February 29, 2016.
Shintani Y, Hollingsworth MA, Wheelock MJ, Johnson KR. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006; 66(24): 11745-11753. doi: 10.1158/0008-5472.CAN-06-2322
Imamichi Y, König A, Gress T, Menke A. Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 2007; 26(16): 2381- 2385. doi: 10.1038/sj.onc.1210012
Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011; 286(12): 10495-10504. doi: 10.1074/jbc.M110.195628
Yang X, Staren ED, Howard JM, Iwamura T, Bartsch JE, Appert HE. Invasiveness and MMP expression in pancreatic carcinoma. J Surg Res. 2001; 98(1): 33-39. doi: 10.1006/ jsre.2001.6150
Nagai S, Nakamura M, Yanai K, et al. Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation. Cancer Sci. 2008. 99(7): 1377- 1384. doi: 10.1111/j.1349-7006.2008.00822.x
Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 1992; 7(2): 120-125. doi: 10.1165/ajrcmb/7.2.120
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980; 284(5751): 67-68. doi: 10.1038/284067a0
Maatta M, Soini Y, Liakka A, Autio-Harmainen H. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000; 6(7): 2726-2734. Web site. http://clincancerres.aacrjournals.org/content/6/7/2726. long. Accessed February 29, 2016.
Ellenrieder V, Alber B, Lacher U, et al. Role of MT-MMPs and MMP-2 in pancreatic cancer progression. Int J Cancer. 2000; 85(1): 14-20. doi: 10.1002/(SICI)1097- 0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O
Zhi YH, Song MM, Wang PL, Zhang T, Yin ZY. Suppression of matrix metalloproteinase-2 via RNA interference inhibits pancreatic carcinoma cell invasiveness and adhesion. World J Gastroenterol. 2009; 15(9): 1072-1078. doi: 10.3748/ wjg.15.1072
Tan X, Egami H, Abe M, Nozawa F, Hirota M, Ogawa M. Involvement of MMP-7 in invasion of pancreatic cancer cells through activation of the EGFR mediated MEK-ERK signal transduction pathway. J Clin Pathol. 2005; 58(12): 1242-1248. doi: 10.1136/jcp.2004.025338
Li YJ, Wei ZM, Meng YX, Ji XR. Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol. 2005; 11(14): 2117-23. doi: 10.3748/wjg.v11.i14.2117
Mahlbacher V, Sewing A, Elsässer HP, Kern HF. Hyaluronan is a secretory product of human pancreatic adenocarcinoma cells. Eur J Cell Biol. 1992; 58(1): 28-34. Web site. http://europepmc. org/abstract/med/1644063. Accessed February 29, 2016.
Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3): 418-429. doi: 10.1016/j.ccr.2012.01.007
Baril P, Gangeswaran R, Mahon PC, et al. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene. 2007; 26(14): p. 2082-94. doi: 10.1038/sj.onc.1210009
Kanno A, Satoh K, Masamune A, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. Int J Cancer. 2008; 122(12): 2707-2718. doi: 10.1002/ijc.23332
Esposito I, Penzel R, Chaib-Harrireche M, et al. Tenascin C and annexin II expression in the process of pancreatic carcinogenesis. J Pathol. 2006; 208(5): 673-85. doi: 10.1002/ path.1935
JonesFS,JonesPL.ThetenascinfamilyofECMglycoproteins: structure,function,andregulationduringembryonicdevelopment and tissue remodeling. Dev Dyn. 2000; 218(2): 235-59. doi: 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2> 3.0.CO;2-G
Juuti A, Nordling S, Louhimo J, Lundin J, Haglund C. Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation. J Clin Pathol. 2004; 57(11): 1151-1155. doi: 10.1136/jcp.2003.015818
Paron I, Berchtold S, Vörös J, et al. Tenascin-C enhances pancreatic cancer cell growth and motility and affects cell adhesion through activation of the integrin pathway. PLoS One. 2011; 6(6): e21684. doi: 10.1371/journal.pone.0021684
Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol. 2007; 25(3): 319-325. doi: 10.1200/JCO.2006.07.8824
Mantoni TS, Schendel RR, Rödel F, et al. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma. Cancer Biol Ther. 2008; 7(11): 1806-1815. doi: 10.4161/cbt.7.11.6846
AlboD,BergerDH,VogelJ,TuszynskiGP.Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer. J Gastrointest Surg. 1999; 3(4): 411-7. doi: 10.1016/S1091-255X(99)80058-4
Qian X, Rothman VL, Nicosia RF, Tuszynski GP. Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production. Pathol Oncol Res. 2001; 7(4): p. 251-259. doi: 10.1007/BF03032381
Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012; 3: 344. doi: 10.3389/fphys.2012.00344
Bachem MG, Zhou S, Buck K, Schneiderhan W, Siech M. Pancreatic stellate cells--role in pancreas cancer. Langenbecks Arch Surg. 2008; 393(6): p. 891-900. doi: 10.1007/s00423-008- 0279-5
Bachem MG, Schünemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology. 2005; 128(4): 907-921. doi: 10.1053/j.gastro.2004.12.036
Fujita H, Ohuchida K, Mizumoto K, et al. Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells. Cancer Sci. 2009; 100(12): 2309-2317. doi: 10.1111/j.1349-7006.2009.01317.x
Xu Z, Vonlaufen A, Phillips PA, et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol. 2010; 177(5): 2585-2596. doi: 10.2353/ajpath.2010.090899
Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013; 108(4): 914-923. doi: 10.1038/bjc.2013.32
Ene-Obong A, Clear AJ, Watt J, et al. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Gastroenterology. 2013; 145(5): 1121-1132. doi: 10.1053/j.gastro.2013.07.025
Wang RF. Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol. 2006; 16(1): 73-79. doi: 10.1016/j.semcancer.2005.07.009
Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012; 21(6): 822-835. doi: 10.1016/j. ccr.2012.04.025
Chen R, Pan S, Ottenhof NA, et al. Stromal galectin-1 ex-pression is associated with long-term survival in resectable pan-creatic ductal adenocarcinoma. Cancer Biol Ther. 2012; 13(10): 899-907. doi: 10.4161/cbt.20842
Ma Y, Hwang RF, Logsdon CD, Ullrich SE. Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer. Cancer Res. 2013; 73(13): p. 3927-37. doi: 10.1158/0008- 5472
Ceyhan GO, Bergmann F, Kadihasanoglu M, et al. Pancreatic neuropathy and neuropathic pain--a comprehensive pathomorphological study of 546 cases. Gastroenterology. 2009; 136(1): 177-186. doi: 10.1053/j.gastro.2008.09.029
Koide N, Yamada T, Shibata R, et al. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res. 2006; 12(8): 2419-2426. doi: 10.1158/1078-0432. CCR-05-1852
Meduri F, Diana F, Merenda R, et al. Pancreatic cancer and retroperitoneal neural tissue invasion. Its implication for survival following radical surgery. Zentralbl Pathol. 1994; 140(3): 277- 279. Web site. http://europepmc.org/abstract/med/7947636. Accessed February 29, 2016.
Zhu Z, Kleeff J, Kayed H, et al. Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol Carcinog. 2002; 35(3): 138-47. doi: 10.1002/mc.10083
Li X, Wang Z, Ma Q, et al. Sonic hedgehog paracrine signaling activates stromal cells to promote perineural invasion in pancreatic cancer. Clin Cancer Res. 2014; 20(16): 4326-4338. doi: 10.1158/1078-0432
Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA. Neurotrophins and Trk receptors in human pancreaticductaladenocarcinoma:expressionpatternsandeffects on in vitro invasive behavior. Int J Cancer. 1999; 81(3): 417- 427. doi: 10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6
Zhu ZW, Friess H, Wang L, et al. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells. Clin Cancer Res. 2001; 7(1): 105-112. Web site. http:// clincancerres.aacrjournals.org/content/7/1/105.long. Accessed February 29, 2016.
Okada Y, Eibl G, Guha S, Duffy JP, Reber HA, Hines OJ. Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis. 2004; 21(4): 285-292. doi: 10.1023/B:CL IN.0000046131.24625.54
Ceyhan GO, Giese NA, Erkan M, et al.The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg. 2006; 244(2): 274-281. doi: 10.1097/01.sla.0000217642.68697.55
Okada Y, Eibl G, Duffy JP, Reber HA, Hines OJ. Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery. 2003; 134(2): 293-299. doi: 10.1067/ msy.2003.239
Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res. 2008; 14(19): 5995-6004. doi: 10.1158/1078-0432.CCR-08- 0291
Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J Gastroenterol. 2014; 20(9): 2335-2342. doi: 10.3748/wjg.v20.i9.2335
Hwang RF, Moore TT, Hattersley MM, et al. Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer. Mol Cancer Res. 2012; 10(9): 1147-1157. doi: 10.1158/1541-7786
Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut. 2008; 57(10): 1420-1430. doi: 10.1136/ gut.2007.148189
Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009; 324(5933): 1457-1461. doi: 10.1126/science.1171362
Tahara H, Sato K, Yamazaki Y, et al. Transforming growth factor-alpha activates pancreatic stellate cells and may be involved in matrix metalloproteinase-1 upregulation. Lab Invest. 2013; 93(6): 720-732. doi: 10.1038/labinvest.2013.59
Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature. 1997; 390(6659): 465-71. doi: 10.1038/37284
Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet. 2003; 4: 237-56.
Bardeesy N, Cheng KH, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 2006; 20(22): 3130-3146. doi: 10.1101/gad.1478706
He J, Sun X, Qian KQ, Liu X, Wang Z, Chen Y. Protection of cerulein-induced pancreatic fibrosis by pancreas-specific expression of Smad7. Biochim Biophys Acta. 2009; 1792(1): 56- 60. doi: 10.1016/j.bbadis.2008.10.010
Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014; 25(6): 735-747. doi: 10.1016/j.ccr.2014.04.021
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011; 29(34): 4548-4554. doi: 10.1200/JCO.2011.36.5742
Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release. 2013; 170(3): 365-72. doi: 10.1016/j. jconrel.2013.05.041
Masamune A, Hamada S, Kikuta K, et al. The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol. 2013; 48(5): 602-609. doi: 10.3109/00365521.2013.777776
Beatty GL, Torigian DA, Chiorean EG, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013; 19(22): 6286-6295. doi: 10.1158/1078-0432
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.